Protocol Ledger

NCT05519839 · Phase II · COMPLETED

A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine

Interventional Phase II clinical trial protocol NCT05519839 sponsored by Novavax in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-12-30 Enrollment: 1,579 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05519839
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,579 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05519839
Protocol FieldVerified Registry Value
NCT IdentifierNCT05519839
Consolidated Lead SponsorNovavax
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment1,579 participants (ACTUAL)
Registered Start Date2022-12-30
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI